8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 1, 2022

Charlotte’s Web Holdings, Inc.

(Exact name of Registrant as Specified in Its Charter)

British Columbia	000-56364	98-1508633
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

700 Tech Court Louisville, Colorado	80027
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s Telephone Number, Including Area Code: (720) 617-7303

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of exchange on which registered
N/A	N/A	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry Into a Material Definitive Agreement.

Effective as of November 1, 2022, Charlotte’s Web Holdings, Inc. (the “Company”) entered into a Manufacturing and Sales License Agreement (the “Agreement”) with Aphria, Inc., an Ontario corporation, an affiliate of Tilray Brands, Inc. (“Tilray”), pursuant to which the parties entered into a strategic alliance by which Tilray will have the rights to licensing, manufacturing, quality, marketing and distribution of Charlotte’s Web^TM CBD hemp extract products in Canada. Pursuant to the Agreement, Tilray has the exclusive rights to the sale and distribution of Charlotte’s Web^TM CBD hemp extract products in all channels, including medical, adult-use, and pharmacy (when permissible) where such products may be legally sold and distributed in Canada. Additionally, Tilray will have the first right exclusively to bring the Company’s new products into Canada. If Tilray fails to exercise such right within 30 days of being given notice by the Company of the proposed product introduction, the Company will have the right to seek an alternative distributor for such product introduction in Canada. Under the Agreement, Tilray’s responsibilities include sourcing raw materials, manufacturing the Company’s products, and packaging and labeling the Company’s products, all in accordance with applicable laws, the Company’s quality standards and specifications.

In consideration for the Agreement, Tilray has agreed to spend in each calendar year during the term of the Agreement (other than 2022) a minimum of five percent (5%) of net sales per year on advertising, retail marketing, direct to consumer advertising, and similar third-party marketing expenditures for the Company’s products. In addition, Tilray will spend an additional $250,000 (Canadian dollars) on marketing in the first contract year following 2022 to launch the Company’s brand into the Canadian market. Tilray will also pay the Company a monthly royalty of 10% of all net sales revenue received by Tilray from sales to third-party entities during the prior month.

The Agreement expires on October 31, 2026, unless earlier terminated by either party in accordance with the terms of the Agreement. The Agreement is also subject to termination for convenience by either party upon 6 months’ notice given on or after October 31, 2024.

Other than the Agreement, there are no other agreements or relationship between the Company and Tilray.

The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, which is included as Exhibit 10.1 to this Current Report on Form 8-K.

Forward-Looking Statements

Certain statements in this Current Report on Form 8-K constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, but not necessarily in all cases, forward-looking statements can be identified by the ‎use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", ‎‎"is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and ‎phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be ‎achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or ‎circumstances contain forward-looking statements. ‎ Forward looking statements in this Current Report on Form 8-K include expectations with respect to the consideration payable to the Company by Tilray under the Agreement.

Forward looking statements are not historical facts but instead represent management's current ‎expectations, estimates and projections regarding the future of the Company’s business, future plans, strategies, projections, anticipated events ‎and trends, the economy and other future conditions. Forward-looking statements are necessarily based on a number of opinions, ‎assumptions and estimates that, while considered reasonable by the Company as of the date of this Current Report on Form 8-K, are subject to ‎known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, ‎performance or achievements to be materially different from those expressed or implied by such forward-looking statements. Important factors that could cause actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the factors discussed throughout the "Risk Factors" section in the Company's most recently filed Annual Report on Form 10-K and quarterly report on Form 10-Q and other filings with the Securities and Exchange Commission available on www.SEC.com and the Company's most recently filed annual information form available on www.SEDAR.com. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Item 8.01. Other Events.

On November 2, 2022, the Company issued a joint press release with Tilray announcing their strategic alliance for licensing, manufacturing, quality, marketing and distribution of Charlotte’s Web^TM CBD hemp extract products in Canada. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01.		Financial Statements and Exhibits.
	(d)	Exhibits:

Exhibit No.	Description
10.1†	Manufacturing and Sales License Agreement, effective November 1, 2022 by and among Aphria, Inc. and Charlotte’s Web, Inc.
99.1	Joint Press Release of Charlotte’s Web Holdings, Inc. and Tilray Brands, Inc. dated as of November 2, 2022.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document
†	Exhibits, schedules and annexes have been omitted pursuant to Item 601(a)(5) of Regulation S-K and will be supplementally provided to the SEC upon request.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	CHARLOTTE’S WEB HOLDINGS, INC.
Date: November 4, 2022	By:	/s/ Stephen Rogers
		Stephen Rogers
		Senior Vice President - General Counsel and Corporate Secretary

EX-10.1

Exhibit 10.1

MANUFACTURING AND SALES LICENSE AGREEMENT

This Manufacturing and Sales License Agreement (this “Agreement”) is entered into and made effective as of October 31, 2022 (the “Effective Date”), by and between Aphria, Inc., an Ontario corporation (the “Company”) with a registered office at 98 Talbot St. W., Leamington, ON N8H 1M8, and Charlotte’s Web, Inc., a Delaware, USA corporation headquartered at 700 Tech Ct., Louisville, CO 80027 (“CW”). Each of the Company and CW are referred to herein as a “Party” and collectively as the “Parties.”

RECITALS:

1. CW markets and sells certain products, based upon proprietary and in some cases patented hemp cultivars, including cannabidiol, other cannabinoids, and other substances derived from the hemp plant (“Hemp Extract”) in the United States and elsewhere. CW has registered its proprietary hemp cultivars in Canada but is not a licensed producer of cannabis or Hemp Extract products in Canada.

2. The Company is a licensed producer of medical and adult-use cannabis products in Canada.

3. CW has contracted with a Canadian hemp grower, HyTech Production, Inc. (“Cultivator”), to cultivate Biomass (defined below) from CW’s proprietary cultivars. CW’s Cultivator is registered with and licensed by Canadian government agencies as required by law.

4. CW and the Company intend that the Company will obtain delivery of the Biomass from Cultivator and then manufacture same into the hemp-based Products (defined below), and then sell the Products to provincial government-licensed distributors of cannabis and Hemp Extract products, with the Company paying CW a royalty on all such sales.

NOW, THEREFORE, in consideration of the following promises and for other and further consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, desiring to be legally bound, do hereby covenant and agree as follows.

1. Definitions. In addition to the various defined terms set forth elsewhere in this Agreement, the following terms each shall have the meaning set forth below:

(a) “Affiliate” shall mean one legal person who owns a majority of the voting stock of, or controls, is controlled by, or is under common control of, another legal person.

(b) “Biomass” shall mean hemp raw material cultivated from CW proprietary hemp cultivars harvested and processed and meeting Health Canada specifications intended to create the Products.

(c) “Contract Year” shall mean any full calendar year during the Term, starting from the Effective Date, as well as a partial calendar year at the beginning and/or end of the Term.

(d) “Dollar” shall mean the Canadian Dollar unless otherwise specified.

(e) “Net Sales” shall mean the net sales revenues derived by the Company from its sales of Products less discounts, fees, returns, promotions, and applicable taxes (including for clarity excise taxes imposed by the Canada Revenue Agency and regulatory fees imposed by Health Canada).

Page 1 of 13

(f) “Products” shall mean those particular CW products which hereafter may be listed on Exhibit A hereto, as may be amended from time to time, and as such Products may be regulated under the Cannabis Act (S.C. 2018, c. 16) or other applicable legislation and destined for sale in the Territory.

1313

(g) “Territory” shall mean Canada.

2. License to Manufacture and Sell Products; Pricing; Forecast.

 a) Subject to the terms and conditions set out herein, including the grant of license by CW to Company in Section 7, CW hereby grants to the Company a non-transferable, non-sublicensable, exclusive license to (i) extract Hemp Extract from the biomass received from the Cultivator for the sole purpose of manufacturing Products within the Territory during the Term, and (ii) manufacture, market, distribute and sell the Products within the Territory during the Term. The Products, which are those which are listed on Exhibit A, may be expanded, or contracted, or otherwise amended, only by mutual written agreement of the Parties from time to time. However, any discontinued product may be deleted unilaterally by CW at any time upon thirty (30) days’ notice to the Company.

b) Company shall have sole discretion to set and adjust the pricing of Products during the Term. Company commits to pricing the Products at or above the mean price per mg CBD in the market as the standard price but shall have discretion to implement discounts and promotions as commercially reasonable.

c) Company shall, on the Effective Date and on a quarterly basis thereafter, submit a six-month rolling forecast (the “Forecast”) to CW that includes Company’s good faith estimate of the amount of Products to be produced, including any changes to Specifications permitted or contemplated in accordance with this Agreement, by Company for sale by Company across the Territory during such period.

3. Right to New Product Introduction into the Territory. If at any time CW decides to introduce a new CW cannabis or hemp-based product not then listed on Exhibit A (a “New Product”) into the Territory, the Company will have the exclusive right, to be exercised by Company within thirty (30) days of being given notice (or otherwise being made aware) of the proposed introduction, to bring the New Product into the Territory during the Term of the Agreement. In the event the Company exercises its right in this Section 3, the Parties shall promptly amend Exhibit A of the Agreement to include such New Products(s) as a Product. If the Company does not exercise its right to launch the New Product, CW may seek an alternative partner in the Territory to launch its desired New Product.

4. Exclusivity. The Company shall have the exclusive right to sell and distribute the Products in all channels, including medical, adult-use, and pharmacy (when permissible) where the Products may be legally sold and distributed in the Territory during the Term. Such exclusivity shall extend to New Products only when and if they are added to Exhibit A in accordance with Section 3 above. Except for CW servicing clients that possess a Health Canada Exemption Letter as provided under subsection 140(1) of the Cannabis Act (CA), The Parties further agree and acknowledge that they intend for this provision to survive the earlier expiry or termination of this Agreement until October 31, 2026 if the Agreement is terminated by CW for convenience or by Company for breach pursuant to Section 13. Company shall act as the sole and exclusive channel for the sale of the Products in the Territory; provided, however, in the event of change of applicable laws to allow direct to consumer or broader retail sales (pharmacy sales channel), the Company’s exclusivity would apply only to brick and mortar sales, while Company and CW would both be permitted to engage in direct to consumer ecommerce sales in pharmacy sales channel throughout Territory. The exclusive rights granted to Company are subject to Company meeting the minimum sales goals as provided for in Section 10(b).

Page 2 of 13

5. Biomass Acquisition. Company shall acquire all Biomass needed to produce the Products by entering into a purchase agreement with Cultivator in a form acceptable to Company setting forth all contractual and legal requirements necessary for Company to purchase such Biomass from Cultivator.

6. Manufacturing Process and Requirements.

 (a)       Separation. Company agrees to respect the confidentiality of the recipes, formulas and processes used to manufacture the Products, and to take all possible and necessary measures to protect this information and restrict access to such information to limited and specific employees, consultants, advisors, competitors, and prospective customers on a need-to-know basis.

 (b)       Manufacturing Standards & Procedures. Company shall adopt and maintain quality assurance procedures, perform periodic quality control tests, conduct audits and implement measures to ensure that all of the Products manufactured hereunder conform to applicable (as defined below), “Good Production Practices Guidelines” promulgated by Health Canada, any other standards, protocols, audits or tests reasonably requested by CW, its customers or distributors, the applicable Specifications (as defined below) and other applicable requirements of any governmental authority (collectively the “QA Procedures”). In the licensed Territory the Company will follow Health Canada’s Cannabis Act Regulations. CW will audit to ensure the quality standards are followed under Health Canada and its requirements. Company agrees to use industry best practices to regularly monitor and maintain (i) the quality of raw materials, and (ii) the quality and sanitary condition of all equipment used to store, handle, process, manufacture, package and deliver the Products. Company will ensure that it has qualified staff that can oversee quality and sanitary conditions of its factory, as well as professional staff that can ensure the quality of raw materials. At the request of CW, Company shall promptly submit to CW in writing a description of its QA Procedures and shall adopt and incorporate in the Specifications such additional quality control procedures (which shall be included in the definition of (“QA Procedures”) as CW may require, pending prior approval and alignment with Company. If any direct conflict in QA Procedures is found between this Agreement and the separate Quality Agreement entered by both Parties, the Quality Agreement procedures will prevail. Representatives of CW may (but shall not be obligated to), during normal business hours and upon at least forty-eight (48) hours prior notice to Company, visit and inspect Company’s facilities to view production, audit waste, collaborate on best practices and/or perform such quality control testing according to established and agreed upon specifications, methods, and labs, of the Products as CW determines to be reasonably necessary or desirable to ensure Company’s compliance with the provisions of this Agreement. Company represents and warrants that its manufacturing facilities are (and during the term of this Agreement will be) registered with all required government agencies and in compliance with all applicable regulations and standards. For purposes of this Agreement, “GPPs” means current good production practices, applicable guidance documents issued by Health Canada and similar requirements of other countries to the extent that they are relevant (as applicable).

(c)       Sourcing of Raw Materials and Packaging. Company agrees it will only use raw materials and packaging materials (“Materials”) sourced pursuant to the Specifications (as defined herein) for the manufacture of Product and approved for use in the facility by the Company. The Parties acknowledge that for Company to satisfy its obligations under this Agreement, Company shall purchase Materials and make certain other expenditures in connection with the manufacture of the Products. Thus, Company shall procure the Materials based upon the applicable demand for the Products. Company is responsible for procuring all Materials from suppliers approved by CW and ensuring the quality of the components through supplier-provided Certificate of Analysis compliance and in accordance with Company’s internal procedures for supplier and material approval; provided, that (i) all suppliers of Materials shall be designated by CW or otherwise approved by CW in writing prior to use; (ii) Company and CW will work together closely to source Materials and share best practices to maximize efficiencies; (iii) CW has the right to review Company’s quality control procedures, observe production and collaborate on best practices; and (iv) Company shall employ commercially reasonable efforts to control costs associated with the purchase of Materials.

Page 3 of 13

7.       Packaging, Labels and Marketing Materials. Company shall be solely responsible for ensuring that all packaging, labeling and marketing materials relating to the Products are in compliance with any applicable federal or provincial laws and regulations. CW hereby grants to the Company a limited, royalty-free, non-transferable, exclusive license during the Term of this Agreement to use CW’s tradenames, trademarks and logos hereto (the “CW Trademarks”), solely in the Territory for the purposes of producing and distributing the packaging, labeling, and marketing materials for the Products in accordance with this Agreement. The Company undertakes to appropriately mark the Products and the marketing material to identify CW as the owner of such CW Trademarks, in a manner that is clear and evident to third parties, and mention that the use of the CW Trademarks is under license by the Company. All Product packaging, labels, and marketing materials, used by the Company with respect to the Products or including the CW Trademarks shall be preapproved in writing by CW and approved by the Company for use in Canada according to the Health Canada’s Cannabis Regulations and Packaging and labelling guide for cannabis products.

8. Quality Standards; Testing of Products.

(a) Specifications. Company shall manufacture the Products in accordance with the Product specifications (the “Specifications”) set forth in the Quality Agreement attached hereto as Exhibit B. CW may amend the Specifications at any time. The Parties shall mutually agree on the allocation of expenses and costs required to implement any proposed changes to Specifications and pricing amendments prior to the effectiveness of the proposed amendment. Company shall then implement such amendment in a mutually agreed upon time frame. CW’s Quality Control and New Product Development departments shall create and send to the Company specific criteria to be incorporated into the Specifications for the New Product, including (a) the specifications of the Hemp Extract to be used in the New Product; (b) the specifications of such New Product itself; and (c) the quality release specifications for such New Product. Company shall not make any change or alteration in the Specifications or the design or manufacture of any Products (or any part or component thereof) (“Change”) without CW’s prior written consent. If a Change is required in order to correct a defect in, or a nonconformity to, the Specifications of any Product (whether such defect or nonconformity is discovered by CW or Company), then Company shall make such Change and shall bear any design, engineering, materials, or manufacturing costs incurred in making such Change.

(b) Testing and Inspection. The Company shall permit CW or its agent, at CW’s expense, to conduct periodic tests of the quality of the Products manufactured by the Company, within a reasonable timeframe from the point of manufacture, in accordance with the Cannabis Regulations, and with the Specifications, and to verify that they continue to meet the Specifications and are in compliance with any applicable laws or regulations, as well as periodic inspections of the Company’s extraction and manufacturing facilities.

(c) Compliance with Laws; Recalls. It shall be the Company’s responsibility to comply with all applicable federal, provincial and other laws and regulations involved in the Company’s carrying out its extraction, manufacturing, marketing, distribution, sales and other duties as provided herein. The Company shall report to CW, within five (5) days of receipt thereof, any notice or demand for a Product recall in the Territory. However, the handling of such recall shall be solely the responsibility of the Company, at its sole cost and expense, and the Company shall fully indemnify CW and save CW harmless from any cost, expense or liability (including, without limitation, legal fees) incurred by CW as a consequence of any breach or alleged breach by the Company of any such laws or regulations, or as a consequence of any such recall demand.

Page 4 of 13

9. Permitted Use of Third-Party Distributor.

Company within its sole discretion may appoint one or more entities to transport distribute, promote, market and sell the Products in the Territory (“Distributor”). Distributor shall not market, sell or distribute Products outside of the Territory.

10. Marketing Budgets and Expenditures; Minimum Sales Goals.

(a) Minimum Marketing and Sales Spending. Company agrees to spend, in each Contract Year (other than 2022) a minimum of five percent (5%) of Net Sales per year on advertising, retail marketing, direct to consumer advertising, and similar third-party marketing expenditures for the Products. In addition, the Company agrees to spend an additional $250,000 (Canadian dollars) on marketing in the first Contract Year following 2022 to launch the CW brand into the Canadian market. Failure to spend this amount in any such Contract Year shall be deemed a material breach of this Agreement. All marketing and promotional materials relating to the Products shall be subject to CW’s prior written approval.

(b) Minimum Sales Goals. The Parties agree to the minimum sales goals outlined in Exhibit C hereto. If Company fails to meet minimum sales goals in any such Contract Year, exclusivity granted to Company pursuant to Section 4 shall cease automatically and in advance of written notice; however, all other terms of the Agreement will continue in full force and effect.

11. Royalties.

(a)       Royalty Payments. Within twenty (20) days following the end of each month of a Contract Year, the Company shall send to CW an itemized report of all Net Sales revenue received by the Company from sales to third-party entities, including, but not limited to, direct-to-consumers, distributors, and provincial boards, during the previous month (itemizing each sold Product by SKU, volume and price, noting any applicable discounts permitted hereunder). Within forty-five (45) days following the end of each month of a Contract Year, the Company shall remit to CW, in immediately available funds payment for ten percent (10%) for the Net Sales for such month in Canadian dollars.

(b)       Withholding Tax. To the extent required by any applicable law, the Company may withhold from any royalty payment to CW an amount equivalent to any applicable withholding tax. If the Canada Revenue Agency (“CRA”) or any other authority asserts a claim that the Company did not properly withhold tax from amounts paid to CW, the Company will be responsible for that assessment.  If the assertion is caused by CW (because the appropriate form was not delivered, was not properly executed, or because CW failed to notify the Company of a change in circumstances that rendered a change to the withholding requirements) then CW shall indemnify the Company fully for all amounts paid, directly or indirectly, by the Company as tax or otherwise, including penalties and interest.  In this situation, CW retains the right to challenge the assessment at their own expense.  CW shall be granted the opportunity to submit the necessary forms to the Company and CRA (when appropriate) to obtain the reduced treaty withholding rate. 

Page 5 of 13

12. Audit Rights to Support Royalties. CW shall have the right, upon not less than twenty (20) business days’ notice, no more than twice (2) in a Contract Year, and at CW’s sole cost and expense (all except as set forth below), to inspect during usual business hours solely those portions of the books or records kept by the Company relating to Net Sales during any quarter during the Term in connection with the payments made in sale of Products or transactions contemplated by the Agreement. CW shall always be accompanied by a representative of Company while in Company’s facility or office. Each audit shall be conducted by independent auditors and as efficiently as possible and with as little disruption to the business operations of Company as reasonably possible. If during an audit it is found that the Company has underpaid the royalty owed CW by more than the greater of 10% or $10,000 in any annual period, then CW shall be entitled to the following: i) Company paying CW’s costs and expenses for carrying out the audit and CW recovering an additional audit during the Contract Year. Should CW find through independent auditors that Company has underpaid the royalty owed CW, per the above criteria, on two occasions during the Contract Year, it shall have a right to terminate the Agreement for breach.

13. Term and Termination for Convenience. This Agreement shall commence on the Effective Date and shall continue for a period of four (4) years until October 31, 2026, unless and until terminated as provided herein (the “Term”). This Agreement may be terminated for convenience effective at any time on or after October 31, 2024, by either Party upon six (6) months’ prior written notice to the other Party.

14. Termination for Cause. Notwithstanding the foregoing, this Agreement may be terminated by a Party at any time on immediate notice for cause as follows:

(a)       Termination for Breach. This Agreement shall terminate within thirty (30) days after written notice of termination by one Party to the other for a material breach of any provision of this Agreement, or for failure to meet Minimum Marketing and Sales Spend as provided in Section 10(a) or underpayments found under audit as provided in Section 12, unless such breach is cured within such thirty-day period (if curable). Such termination shall not prejudice the rights of the non-breaching Party, who still shall have all of the rights and remedies available to it in this Agreement, at law, in equity, or otherwise. Failure to pay a royalty or other sum when due hereunder shall be deemed a material breach of this Agreement unless cured within such thirty-day period.

(b) Termination for Bankruptcy. This Agreement shall terminate immediately and automatically if an assignment is made of either Party's business for the benefit of creditors; if a receiver, trustee in bankruptcy, or like official is appointed to take all or part of either Party's property; or if either Party ceases doing business in the ordinary course.

(c) Termination due to Regulatory Authority.

(i) If a regulatory authority (including Health Canada or a provincial government wholesaler) or any third party challenges or refuses to list or sell a Product and such challenge is reasonably likely, in the mutual determination of both Parties, to impact the commercial viability of such Product, either Party may, upon thirty (30) days prior written notice to the other Party terminate its rights and obligations under this Agreement with respect to the Products that are subject to such challenge; and 

(ii) If a regulatory authority provides notice to a Party that it intends to seek the withdrawal or prohibition from the market of any of the Products, the applicable Party, at its sole discretion, shall have the right, but not the obligation to challenge the regulatory authority’s proposed action. If, following a challenge, the regulatory authority prevails in its effort to withdraw from the market any of the Products, as evidenced by a final, non- appealable administrative or legal order, then either Party may immediately upon written notice to the other Party terminate its rights and obligations under this Agreement with respect to the Products that are subject to such withdrawal without penalty or recourse, relating to the Products that are subject to such withdrawal. In the event that a Party determines not to challenge the proposed regulatory action, the other Party may immediately upon written notice to such Party terminate its rights and obligations under this Agreement with respect to such Products.

Page 6 of 13

15. Effect of Expiration or Termination. In the event of expiration or termination of this Agreement:

(a) Outstanding Royalties and Inventory Sell-Off. The effective date of termination shall constitute the final day of the Term and all royalties due for Net Sales revenues through that date shall be paid by the Company to CW, after the termination date, in accordance with the terms hereof. The Company shall be entitled to sell any Products remaining in its possession for a six (6) month period following such expiration or termination; except for terminations pursuant to Section 13 (a) or (b), in which case the Company must immediately cease all sales activity of Products. CW shall be paid by the Company all royalty payments due for any such sales of such remaining Products during such six (6) month period, even though occurring after the date of termination of this Agreement. The Parties agree to take all steps reasonably required to give effect to the termination of this Agreement, including providing for continued operation and utilization by the Company of the Materials and Products to fulfill existing orders received prior to the effective date of termination.

(b) Survival: Upon termination of this Agreement, the provisions of Sections 4, 15, 16, 18, 19, 20, 21, and 24 shall survive for a period of two (2) years. Termination or expiry of this Agreement shall not affect any rights accrued prior to termination or expiration. For greater certainty, the termination or expiration of this Agreement shall not prejudice or affect the rights of any Party against the other in respect of any breach of this Agreement or in respect of any amounts payable in respect of any period prior to such termination or expiration. Termination of this Agreement will not release either Party of the obligations and liabilities of such Party accruing up to the effective date of such termination.

(c) Holding Out. Subject to Company’s inventory sell-off rights in Section 15(a) and all associated rights required to effect same, immediately upon any termination, the Company shall cease to hold itself out as an authorized manufacturer or seller of CW. The license granted hereunder shall immediately terminate and Company shall discontinue any and all use of all CW Trademarks (except as is necessary to sell out its remaining Products as provided above) and shall remove all signs and other indication of its former affiliation with CW from its web site and elsewhere. Upon termination, the Company promptly shall return all materials containing CW’s confidential information, Trademarks and/or intellectual property to CW.

16. Indemnification; Liability.

(a) Each Party shall indemnify, defend, and hold harmless the other Party, its Affiliates, and their respective directors, officers, representatives and employees from and against any and all damages, losses, liabilities costs and expenses of any kind or nature, including without limitation, reasonable costs and attorney’s fees, in connection with any and all suits, investigations, claims, or demands by third parties to the extent resulting from or arising out of (i) any breach by a Party, its Affiliates or their respective officers, directors, employees, or representatives of any representation or warranty of that Party under this Agreement (ii) any negligence or willful misconduct by a Party , its Affiliates or their respective officers, directors, employees, or representative.

(b) Other than in respect of claims: (a) for breaches of confidentiality, (b) for intellectual property infringement, misappropriation or violations, (c) involving serious bodily harm or death, or (d) relating to payment obligations under this Agreement no event shall (x) either Party be liable to the other Party under this Agreement for any indirect, consequential, special, incidental or punitive damages, or loss of profit, loss of data or loss of savings, in connection with this Agreement; and (y) the aggregate liability of either Party to the other Party under this Agreement exceed the amount of fees paid by Company to CW under this Agreement in the one (1) year period immediately preceding the event giving rise to the claim. The foregoing exclusion and limitation of liability shall apply regardless of the form of action, whether based in contract, tort (including negligence) or any other legal theory, whether such damage or loss was foreseeable and whether or not such Party has been advised of the possibility of such.

Page 7 of 13

17. Representations and Warranties.

(a) Each Party is duly organized and validly existing under the laws of its jurisdiction of formation.

(b) Each Party is duly qualified to do business and is in good standing in every jurisdiction in which such qualification is required for purposes of this Agreement.

(c) Each Party has the full right, power, and authority to enter into this Agreement, to grant each other the rights set forth, including intellectual property rights, and to perform its obligations hereunder.

(d) The execution of this Agreement has been duly authorized by all necessary action on the part of each Party. This Agreement constitutes the legal, valid, and binding obligation of each Party in accordance with its terms.

18. Company Insurance. The Company shall maintain, during the term of this Agreement and for two (2) years after the termination or expiration of this Agreement, Commercial General Liability insurance with appropriate endorsements, with per-claim limitations and aggregate liability limitations in the amount of at least five (5) million dollars. The Company shall provide CW with a certificate of such insurance promptly upon request and shall include CW as a named insured thereon upon request, if feasible. The Company’s obligation to obtain the insurance specified herein does not waive or release the Company’s liabilities or duties to indemnify.

19. Assignment and No Third Party Beneficiaries.

(a) Neither Party may assign this Agreement or delegate any of its duties or obligations hereunder to any third party without the prior written consent of the other Party, not to be unreasonably withhold. Notwithstanding the foregoing, either Party may be permitted to assign this Agreement in connection with a merger, acquisition, corporate reorganization, or sale of all or substantially all of its assets upon notice to the other Party. This Agreement shall be binding upon, and shall inure to the benefit of, all rightful assignees and successors to the Parties.

(b) The provisions of this Agreement are for the benefit of the Parties and not for any other person, including without limitation the Cultivator or Distributor.

20. Dispute Resolution.

(a) Any dispute, controversy or claim arising out of or in connection with this Agreement, including any question regarding its existence, validity, interpretation, breach or termination (a “Litigious Dispute”), shall be referred, upon written notice (a “Notice of Dispute”) given by one Party to the other, to a senior executive from each Party. The senior executives shall seek to resolve the Litigious Dispute on an amicable basis within thirty (30) days of the Notice of Dispute being received. If both Parties agree, the Litigious Dispute may be referred to mediation before a mediator mutually agreed upon by the Parties or, DR Institute of Canada, Inc. (the “ADRIC”). The Parties all equally share the costs of the mediator, the mediation venue and the ADRIC.

Page 8 of 13

(b) If the Litigious Dispute is not resolved within thirty (30) days of receipt of the Dispute Notice, the Litigious Dispute shall be referred to and finally resolved by arbitration in accordance with the Arbitration Rules of ADRIC (the “Rules”) but, subject to the agreement of both Parties, the ADRIC is not required to administer the arbitration (the “Arbitration”). Unless otherwise agreed to in writing by the Parties:

i. the Arbitration shall be conducted before one (1) arbitrator mutually agreed upon by the Parties. If the Parties are unable to agree upon an arbitrator within ten (10) Business Days of the commencement of the Arbitration, the arbitrator shall be appointed in accordance with the Rules and the Arbitration shall proceed thereafter as an administered arbitration under the auspices of ADRIC;

ii. the seat of the Arbitration shall be Toronto, Ontario, Canada;

iii. the language of the Arbitration shall be English;

iv. any award or determination of the arbitrator shall be final and binding on the Parties and there will be no appeal on any ground, including, for certainty, any appeal on a question of law, a question of fact, or a question of mixed fact and law; and

v. all matters relating to the Arbitration, including all documents created in the course of or for the purposes of the Arbitration and any interim or final decision, order, or award in the Arbitration, shall be kept confidential and shall not be disclosed by any Party to any third party (excluding their respective legal counsel and where necessary, financial advisors) without the prior written consent of the other Party, or unless required by Applicable Laws.

21. Confidential Information. The Parties acknowledge the continued existence and enforceability of the mutual non-disclosure agreement between the Parties dated January 5, 2022 in respect of Confidential Information (as defined in such agreement) which may be shared between the Parties and their Affiliates and Representatives (as defined in such agreement). The Parties confirm that the terms of such agreement shall remain in full force and effect and shall apply in respect of the sharing of any Confidential Information hereunder

22. Press Release and Announcement. The Parties intend to issue a joint press release announcing execution of this Agreement following execution. The wording of the joint press release and any other public announcements related to this Agreement shall be approved in writing by both Parties prior to public disclosure.

23. Relationship of the Parties. Nothing in this Agreement shall be construed to create an agency, partnership or joint venture between the Parties hereto, nor shall any similar relationship be deemed to exist between them. Neither Party hereto shall represent itself to third parties as the agent, partner, or joint venturer of the other.

24. Intellectual Property. Except as expressly authorized in accordance with this Agreement, neither Party, by the operation of this Agreement or otherwise, is hereby acquiring any right or interest in any intellectual property right of the other Party, including but not limited to any trademark or trade name owned, used or claimed now or in the future by the other Party. For the avoidance of any doubt, all intellectual property and proprietary rights, title and interest in or to the Products or the CW Trademarks, or otherwise related thereto, are and shall remain the unique and exclusive property of CW. Company acknowledges that the CW’s brand and all of its associated and derivative intellectual property and commercially sensitive information is solely owned by CW, that Company has no ownership interest, encumbrance, lien, or title in the brand, its trademarks, its formulas, its specifications, its trade dress, its recipes, its production processes, techniques, and/or any other intellectual property or proprietary information (“CW Intellectual Property”). Company commits to respect and protect the CW Intellectual Property. Company will recognize any unique process that is specific and exclusive in the industry to CW as CW Intellectual Property. However, Company cannot be constrained from the broader use of typical industry practices and processes by their use in the making of Products. CW recognizes that Company, as a manufacturer, is knowledgeable in the field and that certain generic and generally used processes and knowledge cannot become the property of CW or any other entity. Company agrees that no express or implied licenses or other rights relating to any CW Intellectual Property are provided to Company hereunder, other than to the extent necessary to complete the relevant activities of this Agreement or as otherwise specifically set forth herein. Title in all CW Intellectual Property shall remain at all times in CW. Company agrees that CW Intellectual Property shall: (i) only be used as specified in writing by CW and not for any other purpose; (ii) only be made accessible to those employees of Company who need access in order to complete the relevant activities of this Agreement; (iii} be used in compliance at all times with all Applicable Laws; (iv) be carefully secured and not be transferred to any affiliate or third party without the explicit prior written consent of CW; (v) not be reverse engineered; and (vi) not be subjected to testing procedures not specifically requested by CW as part of this Agreement. All rights in and to the processes, procedures, techniques, know-how and trade secrets relating to the manufacturing, packaging, labelling, and testing of cannabis used in the production of the Products shall remain the exclusive property of Company (“Company Intellectual Property”). CW acknowledges that CW has no ownership interest, encumbrance, lien, or title in the Company Intellectual Property. CW commits to respect and protect the Company Intellectual Property. CW will recognize any unique process that is specific and exclusive in the industry to Company as Company Intellectual Property

Page 9 of 13

25. Foreign Corrupt Practices Act. The Company recognizes that CW is a United States corporation, and as such has certain legal and ethical responsibilities to avoid involvement with certain types of transactions. The Company hereby represents and warrants that it has not, and covenants that it shall not during the term of this Agreement, directly or indirectly, give, offer, authorize, pay or promise to pay any money or anything of value to any Foreign Official (defined below), or to any political party or party official or candidate for political office, for the purpose of influencing any act or inducing such Foreign Official or other person or entity to use his influence to assist the Company or CW in obtaining or retaining any sales or business relating to the Products. For purposes of this paragraph, "Foreign Official" shall mean an officer or employee of a government (other than the United States) or any department, agency or instrumentality thereof, or any person or entity acting in an official capacity for or on behalf of any such government or department, agency or instrumentality.

26. Insider Trading. Both Parties are owned by parents whose stock is publicly traded. It is possible that, in the course of its actions hereunder, a Party might come into contact with material undisclosed information about the other Party. Each Party understands that the securities laws of Canada and the United States both forbid buying, selling or otherwise trading publicly traded stock upon such information until it becomes a matter of public record, and will be responsible for actions taken by any of its Representatives in violation thereof.

27. Entire Agreement; Further Assurances. This Agreement comprises the full and entire understanding and agreement between the parties with regard to the subject matter hereof, and supersedes all oral or written agreements and understandings with regard to such subject matter hereof. Each of Company and CW will from time to time execute and deliver all such further documents and instruments and do all acts and things as the other Party may reasonably require to effectively carry out or better evidence or perfect the full intent and meaning of this Agreement.

Page 10 of 13

28. Severability. In case any provision of this Agreement shall be invalid, illegal or unenforceable, such provision shall be reformed to the extent necessary to permit enforcement thereof, and the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.

29. Equitable Remedies. Each Party hereto hereby confirms that damages at law may be an inadequate remedy for the breach or threatened breach of this Agreement and agrees that, in the event of a breach or threatened breach by a Party of any provision hereof, the other Party's rights and obligations hereunder shall be enforceable by specific performance, injunction, or other equitable remedy, in addition to and not in lieu of any rights to damages at law or other rights provided by statute or otherwise for a breach or threatened breach of any provision hereof. Accordingly, each Party hereto hereby waives and agrees not to assert any objection to such equitable relief based upon the purported existence of an adequate remedy at law, notwithstanding that another Party may also assert claims for damages at law or other claims as an alternative to, or in addition to, such equitable relief.

30. Notices. Notices and other communications hereunder shall be given to the parties at their respective address as set forth on the initial paragraph hereof, or to such other addresses as to which the parties may subsequently notify each other in writing. All notices and other communications hereunder shall be in writing, and shall be deemed to have been given at the date of actual receipt, or when actual delivery to such address or tender of delivery has been confirmed in writing by an unaffiliated delivery service. E-mails and other forms of electronic communication shall constitute valid notice (or communication) only if receipt thereof is thereafter acknowledged and confirmed by the recipient, by means of the same medium or another medium permitted hereunder.

31. Governing Law. This Agreement shall be governed and construed in accordance with the laws of the Province of Ontario and the federal statutes of Canada applicable therein, and each Party agree that any litigation arising out of or relating to this Agreement will be submitted to the exclusive jurisdiction of the courts of the Province of Ontario, Canada, except that a Party may enforce a decision of such courts, and may seek injunctive relief only, in any court with jurisdiction over the other Party.

32. Force Majeure. A Party shall be excused for any failure or delay in performing any of its obligations under this Agreement, if such failure or delay is caused by Force Majeure, provided that such affected Party shall (a) promptly notify the other Party in writing of the occurrence or circumstance upon which it intends to rely to excuse its performance, and (b) use commercially reasonable efforts to promptly resume performance after the cause of such delay is removed. For purposes of this Agreement, “Force Majeure” shall mean any act of God, accident, explosion, fire, epidemic and pandemic, storm, earthquake, flood, drought, riot, insurrection, embargo, civil commotion, war, act of war, terrorism, act or order of any Governmental Authority or inability to obtain or delay in the delivery of raw materials, parts or completed merchandise by the supplier, strikes or other labor difficulties, or any other cause not under the control of the affected Party. In the event that the Force Majeure shall continue for a period of sixty (60) days, either Party shall have the right to immediately terminate this Agreement following written notice to the other Party.

33. Amendments. Changes, amendments, or modification in, or additions to, any provision of this Agreement shall be made only by a written instrument executed by both of the Parties.

Page 11 of 13

34. Delays or Omissions; Waivers. No delay or omission to exercise any right, power or remedy inuring to any Party, upon any breach or default of any Party under this Agreement, shall impair any such right, power or remedy of such Party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any Party of any breach or default under this Agreement, or any waiver on the part of any Party of any provisions or conditions of this Agreement must be made in writing by the Party to be charged therewith and shall be effective only to the extent specifically set forth in such writing. All remedies either under this Agreement or by law or otherwise afforded to any holder, shall be cumulative and not alternative.

35. Authorization. Each Party hereby represents and warrants to the other that it is duly constituted as a legal entity in good standing in the jurisdiction of its organization, that it has all necessary authority to enter into this Agreement, that doing so will not violate the provisions of any agreement or obligation to which such Party is subject, and that the signer of this Agreement on behalf of such Party is duly authorized to do so.

36. Captions. Captions are for convenience only and shall not be deemed to be a part of this Agreement, nor shall be taken into any consideration in the interpretation hereof.

37. Counterparts. This Agreement may be executed in any number of counterparts, including electronic, each of which shall constitute an original, but which taken together shall constitute one instrument.

38. Construction. Any illegal or invalid provision shall be construed by a court of competent jurisdiction to have the broadest scope permissible under the law of said jurisdiction, and if no validating construction is possible, shall be severable, and all other provisions hereof shall remain in full force and effect.

[signatures on following page]

Page 12 of 13

IN WITNESS WHEREOF, the Parties hereunto set their hands and seals to this Manufacturing and Sales Licensing Agreement as of the date set forth below.

CHARLOTTE’S WEB, INC.

(Signature): By: /s/ Jacques Tortoroli

Name and title of authorized signatory: Jacques Tortoroli, CEO

E-mail:

Date: November 1, 2022

APHRIA INC.

(Signature): By: /s/ Blair MacNeil

Name and title of authorized signatory: Blair MacNeil, President

E-mail:

Date: November 1, 2022

Page 13 of 13

EX-99.1

Exhibit 99.1

   

PRESS RELEASE

Charlotte's Web Enters Strategic Alliance with Tilray for Manufacturing and Distribution in Canada

Charlotte’s Web proprietary full spectrum hemp CBD products available across Canada in 2023

DENVER and LEAMINGTON, ON Nov 2, 2022 - (TSX:CWEB, OTCQX:CWBHF) Charlotte’s Web Holdings, Inc. (“Charlotte’s Web” or the “Company”), the market leader in cannabidiol (“CBD”) hemp extract wellness products, and Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a leading Canadian cannabis consumer packaged goods company, have entered into a strategic alliance which includes licensing, manufacturing, quality, marketing and distribution of Charlotte’s Web^TM CBD hemp extract products in Canada.

Charlotte's Web is the World’s Most Trusted Hemp Extract™ and continues to lead the way for consumer access. For the first time, Canadians will have the ease of nationwide availability of Charlotte’s WebTM full spectrum CBD products through Tilray’s distribution network. Previously, Charlotte’s WebTM hemp extract had only been available to Canadian families that qualified for a special access medical exemption through Health Canada for specific need-states.

“Charlotte’s Web is thrilled to be partnering with Tilray, a respected global category captain. This underscores our strategic expansion into international markets with leading domestic partners by leveraging well-established infrastructure, co-production, and route-to-market capabilities,” said Jacques Tortoroli, Chief Executive Officer of Charlotte’s Web. “Our collective goal is to bring full spectrum CBD-lifestyle wellness options to the Canadian market that will answer consumers’ demand for safe, high quality, trusted CBD products.”

The endeavor will address specific need states for Canadians by replicating the success of Charlotte’s Web’s core offerings in the U.S. with its line of full spectrum hemp extract products, including, naturally flavored oil tinctures, topical creams, and functional gummies for daily wellness and night-time use. Hemp-derived CBD falls under the same regulatory framework in Canada as cannabis; and therefore, Charlotte’s Web will be available through traditional Canadian cannabis sales channels. Establishing Charlotte’s Web’s supply chain and distribution in Canada also prepares for the contemplated introduction of new natural health products regulations and potential ability to sell CBD products through traditional pharmacies in Canada.

“This is an exciting time for the Canadian CBD market as more Canadians seek natural wellness options. Partnering with Charlotte’s Web, the market leading CBD brand, opens new opportunities for Tilray Brands in Canada as we evolve our distribution channels from the dispensary model to natural wellness retail channels and eventually mass retail opportunities. We look forward to launching Charlotte’s Web’s trusted, certified, and tested products across Canada in 2023.” said Blair MacNeil, President, Canada at Tilray.

First availability is expected in early 2023 for hemp extract oil tinctures, followed by gummies and topicals.

“This is a monumental milestone for our Canadian families that have relied on Charlotte’s Web^TM products for years through Health Canada exemption access and marks a new era of wide availability to Charlotte’s Web^TM products,” said Jared Stanley, Co-Founder and COO of Charlotte’s Web. “It was critical that our products were produced only using our proprietary hemp cultivars to ensure quality, efficacy, and consistency. We achieved this through a process that began in 2019 to successfully list our varieties on the Health Canada LOAC (List of Approved Cultivars) in 2021 and working with best-in-class cultivation partners. We are grateful for the meaningful collaboration with Health Canada and Tilray to make Charlotte’s Web^TM products available for all Canadians.”

Under the arrangement, Tilray will acquire and extract Charlotte’s Web^TM proprietary hemp biomass, harvested from Canadian-grown hemp cultivars, and manufacture into final product at their state-of-the-art production facilities in Canada. Quality and manufacturing by Tilray will follow the same proprietary methods and specifications Charlotte’s Web employs in the USA. Tilray will manage distribution through Health Canada’s regulated channels across Canada.

About Tilray Brands

Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people's lives for the better - one person at a time. Tilray Brands delivers on this mission by inspiring and empowering the worldwide community to live their very best life, enhanced by moments of connection and wellbeing. Patients and consumers trust Tilray Brands to be the most responsible, trusted and market leading cannabis consumer products company in the world with a portfolio of innovative, high-quality and beloved brands that address the needs of the consumers, customers and patients we serve. A pioneer in cannabis research, cultivation, and distribution, Tilray Brands' unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.

About Charlotte’s Web Holdings, Inc.

Charlotte's Web Holdings, Inc., a Certified B Corporation headquartered in Denver, is the market leader in innovative hemp extract wellness products. under a family of brands that includes Charlotte's Web™, CBD Medic™, and CBD Clinic™. Charlotte’s Web whole-plant CBD extracts come in full-spectrum and broad-spectrum (THC-free) options, including the world’s only broad-spectrum CBD certified NSF for Sport®, which is the official CBD of Major League Baseball©. Founded by the seven Stanley Brothers, ignited the CBD industry when they came to global prominence with the coverage of a young girl’s astounding reaction to their hemp extract. Their advocacy changed laws, public perception, and research around the vast health potential of plant-based solutions. The Stanleys built their business with the mission to bring safe, botanical options to health seekers worldwide. Charlotte's Web branded premium quality products start with proprietary hemp genetics that are American farm-grown-grown using organic and regenerative cultivation practices. The Company's hemp extracts have naturally occurring botanical compounds including cannabidiol ("CBD"), CBC, CBG, terpenes, flavonoids, and other beneficial compounds. The Company's CW Labs R&D division advances hemp science at a center of excellence in Louisville, Colorado. Charlotte’s Web product categories include CBD oil tinctures (liquid products), CBD gummies (sleep, stress, exercise recovery), CBD capsules, CBD topical creams and lotions, as well as CBD pet products for dogs.  Through its vertically integrated business model, Charlotte’s Web maintains stringent control over product quality and consistency with 20+ product lot testing for quality assurance. Charlotte’s Web products are distributed to more than 15,000 retail locations, over 8,000 health care practitioners, and online through the Company's website at https://www.charlottesweb.com/.

Charlotte's Web's mission is "To unleash the healing powers of botanicals with compassion and science, benefitting the planet and all who live upon it."

© Major League Baseball trademarks and copyrights are used with permission of Major League Baseball. Visit MLB.com.

Forward-Looking Information

Certain information in this news release constitutes forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively, ‎‎"forward-looking information"). In some cases, but not necessarily in all cases, forward looking information can be identified by the ‎use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", ‎‎"is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and ‎phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be ‎achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or ‎circumstances contain forward-looking information. ‎

Statements containing forward-looking information are not historical facts, but instead represent management's current ‎expectations, estimates and projections regarding the future of our business, future plans, strategies, projections, anticipated events ‎and trends, the economy and other future conditions. Forward-looking information is necessarily based on a number of opinions, ‎assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to ‎known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, ‎performance or achievements to be materially different from those expressed or implied by such statements containing forward-looking information. Although these statements containing forward-looking information are based on assumptions the Company considers to be reasonable based on the information ‎available on the date such statements are made, such statements are not guarantees of future performance and readers are cautioned ‎against placing undue reliance on forward-looking information. Specifically, this press release contains forward-looking information relating to, but not limited to: the nationwide availability of the Company’s CBD products in Canada; anticipated consumer trends and corresponding product innovation; ‎anticipated future financial results; international expansion activities and strategy, including partnerships in Greater China, Israel product ‎launch, harvest and planned product sales in Canada, and expansion in UK and EU; sales volume, product, channel and international ‎expansion plans; maintenance or growth of the Company’s market share position; progress continuing in key international markets; the establishment of the Company’s supply chain and distribution network in Canada; the availability of the Company’s CBD products through traditional Canadian cannabis channels and Canadian medical cannabis channels; the availability of the Company’s products in Canada in early 2023; the success of the Company’s alliance with Tilray; suggested ‎regulatory developments; the ability for the Company to access markets in the EU; and the Company's anticipated trajectory, long-term growth expectations and shareholder value creation.‎

The material factors and assumptions used to develop the forward-looking information herein include, but are not limited to, the following: ‎the impact of the COVID-19 pandemic; the regulatory climate in which the Company currently operates and may in the future operate; ‎successful sales of the Company's products; the success of sales and marketing activities; there will be no significant delays in the ‎development and commercialization of the Company's products, including in relation to supply chain disruptions; outcomes from R&D ‎activities; ability for the Company to leverage R&D and brand recognition for product sales; the Company's ability to deal with adverse ‎growing conditions (due to pests, disease, fungus, climate or other factors) in a timely and cost-effective manner; there will be no significant ‎reduction in the availability of qualified and cost-effective human resources; new products will continue to be added to the Company's ‎portfolio; demand for the Company's products will grow in the foreseeable future; there will be no significant barriers to the acceptance of ‎the Company's products in the market, including in international markets; the Company will be able to maintain compliance with applicable ‎contractual and regulatory obligations and requirements; there will be adequate liquidity available to the Company to carry out its ‎operations and business plans; the Company will have sufficient capital to pursue its sales volume, product, channel and international ‎expansion; and products do not develop that would render the Company's current and future product offerings undesirable and the Company ‎is otherwise able to minimize the impact of competition and keep pace with changing consumer preferences.‎

Important factors that could cause actual results and financial condition to differ materially from those indicated in the forward-looking information include, among others, the adverse impact of the COVID-19 pandemic to the Company's operations, supply chain, distribution chain, and to the broader market for ‎the Company's products; revenue fluctuations; nature of government regulations (both domestic and foreign); economic conditions; loss of ‎key customers; retention and availability of executive talent; competing products; common share price volatility; loss of proprietary ‎information; product acceptance; internet and system infrastructure functionality; information technology security; available capital to fund ‎operations and business plans; crop risk; international and political considerations; regulatory changes; ‎and the factors discussed throughout the "Risk Factors" section of the Company's most recently filed annual information form available on www.SEDAR.com and in the Company's most recently filed Annual Report on Form 10-K and quarterly report on Form 10-Q as amended, and other filings with the Securities and Exchange Commission available on www.SEC.gov. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contacts:

Charlotte’s Web Media:  Media@CharlottesWeb.com

Charlotte’s Web Investors:

Cory Pala | Director of Investor Relations

(720) 484-8930

Cory.Pala@CharlottesWeb.com

Tilray Brands Media: Berrin Noorata, news@tilray.com

Tilray Brands Investors:

Raphael Gross

(203) 682-8253

Raphael.Gross@icrinc.com

XML

Cover	Nov. 01, 2022
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Nov. 01, 2022
Entity File Number	000-56364
Entity Registrant Name	Charlotte’s Web Holdings, Inc.
Entity Central Index Key	0001750155
Entity Tax Identification Number	98-1508633
Entity Incorporation, State or Country Code	A1
Entity Address, Address Line One	700 Tech Court
Entity Address, City or Town	Louisville
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80027
City Area Code	720
Local Phone Number	617-7303
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false